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Abstract: When presented with an animal exhibiting signs of keratitis (inflammation of the cornea),
such as impaired vision, mucoid discharges, redness, swelling, and corneal oedema, most veterinari-
ans would think of bacteria, viruses, or fungi as the potential causative agent(s). However, evidence
has arisen in recent years of a possible connection between the protozoan Acanthamoeba and keratitis
in animals. Acanthamoeba infection is underdiagnosed, but potentially common, in animals. In view
of the paucity of evidence regarding Acanthamoeba keratitis (AK) in animals, this review has been
written to increase awareness of veterinary professionals of the potential threat associated with AK
and to stimulate more studies into the extent of occurrence and clinical impact of AK in animals.
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1. Introduction
Acanthamoeba keratitis (AK) is a rare parasitic disease caused by acute infection with
trophozoites of the opportunistic protozoan Acanthamoeba castellanii (Figure 1), which can
have serious adverse health effects on infected individuals. Other Acanthamoeba spp., such
as A. culbertsoni, A. hatchetti, A. griffini, A. rhysodes, A. mauritaniensis, and A. lugdunensis of
the T4 genotype, as well as genotypes T1, T2, T3, T5, T6, and T11, can be also associated
with ocular infections [1]. Clinical symptoms generally include eye pain and photophobia,
however severe disease can lead to blindness if left untreated [2]. Acanthamoeba spp. are
distributed throughout the world and can be established in a wide variety of environ-
mental habitats including soil, mud water reservoirs and hospitals, providing numerous
opportunities for contacts with animals and humans. Human exposure to these organisms
can be very high, as shown by antibody titers in surveyed populations. For example,
a London-based study found that more than 87.7% of the study participants (11 out of
114 healthy asymptomatic individuals) were positive for the presence of secretory anti-A.
castellanii IgA antibody in their saliva [3]. However, having antibodies to A. castellanii does
not necessarily indicate an active infection, as antibodies develop in individuals who have
been exposed to A. castellanii previously. In developed countries, most cases of AK are
related to contact lens use. However, in developing countries, AK can also be associated
with corneal trauma [4].
Acanthamoeba spp. have been reported in a variety of animal species, including
monkeys, dogs, a kangaroo, and an Indian buffalo [5] and even in aquatic animals, such
as fish, amphibian and reptiles [6–8]. An earlier report showed that Acanthamoeba can kill
mice and monkeys [9]. Several animal models, such as rat, hamster, rabbit and micropig,
have been developed to investigate the pathogenesis of AK by infecting these animals
with Acanthamoeba via intrastromal injections or scratching the corneal surface before
placing contaminated contact lenses over the eye [10,11]. Other free-living amoebae with
neuropathogenic potential exist including Balamuthia mandrillaris [12], which has been
detected in dogs, a horse, a sheep and non-human primates [13].
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Although evidence for zoonotic transmission is lacking, given the limited host speci-
ficity, the similarity between humans and some animals in the binding affinity of Acan-
thamoeba to corneal tissue [14], and the proximity between humans and animals in many
settings, it is essential to be aware of the epidemiology, pathogenesis, diagnosis and treat-
ment options for this condition in animals. However, the current status of animals infected
with Acanthamoeba is unknown and the literature exploring the significance of AK in an-
imals is very limited. Therefore, this review aims to raise awareness among veterinary
professionals of the potential threat associated with AK and to stimulate more studies to
investigate the extent of AK in animals.
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Figure 1. Light microscope view of trophozoites of the protozoan Acanthamoeba castellanii; note 
that some of the trophozoites have spiky acanthopodia (arrows) which are seen when the organ-
ism is in the infectious, replicating trophozoite stage. 
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ous study found 2 out of 55 (3.6%) cats examined to be Acanthamoeba positive when cor-
neal scrapings were cultured on non-nutrient agar (NNA) plates. No Acanthamoeba cases 
were detected using direct molecular (18S rRNA gene-based Polymerase Chain Reaction 
[PCR]) analysis. However, genotyping of the culture-positive samples revealed that one 
of the positive cats had the T2 genotype, while the other cat had the T4 genotype, high-
lighting the potential risk of infection for humans and animals. Both of these cats were 
immunocompromised; one tested positive for feline immunodeficiency virus (FIV) and 
Figure 1. Light microscope view of trophozoites of the protozoan Acanthamoeba castellanii; note that
some of the trophozoites have spiky acanthopodia (arrows) which are seen when the organism is in
the infectious, replicating trophozoite stage.
2. Can Animals Be Affected by AK?
Factors such as being a stray or having a compromised immune status are more
likely to predispose animals to Acanthamoeba, because it is an opportunistic organism. A
pre ious study f un 2 out of 55 (3.6%) c ts examined to be Aca thamoeba positive when
corneal scrapings were cultured o non- ut ient agar (NNA) plates. No Acanthamoeba
cases were de cted using direct mol cular (18S rRNA gene-based Polymerase Chain
Reaction [PCR]) analysis. However, enotyping of the culture-positive samples rev aled
that one of the positive cats had the T2 genotype, while the other cat had the T4 genotype,
highlighting th potential risk of nfection for humans and animals. Both of thes cats
were immunocompromis d; one tested positive for feline immunodeficienc virus (FIV)
and the o her for feline leukaemia virus (FeLV) [15]. None of the infected cats showed
any of the characteristic clinical signs of AK seen in humans. However, Acanthamoeba is
detected in cats with ocular pathologies in S itzerland [16] and Malaysia [17]. A previous
study reported that 14.6% (27 out of 184) of the tested conjunctival swab samples from
the eyes of stray dogs were positive for Acanthamoeba [18]; although 7 out of 27 dogs
with evidence of Acanthamoeba did show signs of ocular disease such as conjunctivitis and
keratitis. Neither of the studies conducted by Montoya et al. [15] or Karakuş et al. [18]
obtained a representative sample of the studied population; both obtained their candidates
from local organisations which had animals available. Montoya et al. [15] took advantage
of a health check and neutering programme where stray cats were collected and registered
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every Spring; whereas Karakuş et al. [18] used a previous study sample of stray dogs’
conjunctival swabs taken from eight villages where canine leishmaniasis was endemic.
Given the nature of both studies, this sampling method seems to be appropriate and the
most practical option for sampling animals, including strays which are at greater risk
of AK.
Acanthamoeba infections have also been detected in wild predatory birds in Turkey [19].
Corneal samples were acquired from 18 dead wild birds and 16.6% (3 out of 18) were
identified as positive for Acanthamoeba using PCR, while 5.5% (1 out of 18) tested positive
using the agar plate method. Two strains, T4 and T5, were identified from the DNA
sequencing data. While the sample size of this study was not large enough to make
the data about prevalence and importance of AK in birds conclusive, it did prove that
Acanthamoeba exists in wild bird populations. These studies (Table 1) provide evidence of
the possibility that animals can develop AK or extraocular disseminated acanthamoebiasis.
Infection rates with Acanthamoeba may be higher in animals prone to fighting and acquiring
corneal injuries; foreign particles contaminated with Acanthamoeba can become lodged in
the cat’s eye leading to AK, as has been suggested previously [17].
Table 1. Representative reports of natural Acanthamoeba infections in animals.
Animal Species Samples (n) Country Diagnostic Method Infection Rate Reference
Stray cats 307 Spain
Culturing on non-nutrient
agar (NNA) plates and
18S rRNA gene-based PCR
3.6% positive by culture and
0% by PCR [15]
Stray dogs 184 Turkey 18S rRNA gene-based PCR 14.6% by PCR [18]
Deceased wild
birds 18 Turkey
Culturing on NNA plates and
18S rRNA gene-based PCR
5.5% positive by NNA
culture and 16.6% by PCR [19]
3. Clinical Signs
AK may be the main presentation of Acanthamoeba in humans, although other multi-
systemic manifestations have been reported in two dogs including encephalitis, ascites and
peritonitis, related to the T4 genotype strain infection [20]. Other studies reported a range
of symptoms including anorexia, pyrexia, secretions from nose and eyes, limb stiffness and
neurological manifestations that suggest Acanthamoeba infections are not confined to the
eye and can indeed lead to disease in other body systems in dogs [21–23].
Many biological, immunological and ecological factors define the ability of Acan-
thamoeba species to infect a particular host. Of these, an ability to bind to, and interact with,
the corneal epithelial tissue can be a key factor in dictating the level of pathogenicity of
Acanthamoeba species. Acanthamoeba does not interact in the same way with corneal epithe-
lium of humans, hamsters and pigs as it does with a range of other species such as chickens,
rabbits, rodents, guinea pigs, dogs and horses [14]. This differential selectivity to binding
corneal tissue may be attributed to species-specific differences in the mannose residues on
the surface of the cornea [24]; however, the precise mechanisms remain unknown. As a
result, the clinical signs of AK in animals may differ from those in humans, which may
explain the under-reporting of Acanthamoeba-infected animals. However, remarkable simi-
larities in the clinical and histopathologic features of contact lens-induced AK have been
demonstrated in a micropig model and humans [11]. If Acanthamoeba cannot be detected
by clinical examination, many individuals who come into contact with animals, either for
occupational or pet ownership reasons, may not be aware that their animal is infected with
the pathogenic T4 genotype which could, potentially, be transmitted to the individual and
other animals.
4. Available Diagnostics
Currently, diagnosis of AK in humans is based on history and initial clinical exam-
ination. A characteristic sign of Acanthamoeba is the prominent white ring around the
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cornea [25]. Nonetheless, diagnosis is difficult due to the rarity of the disease and the non-
specific nature of clinical signs [26]. Differential diagnoses often include herpes keratitis in
the earlier stages and fungal keratitis in the later stages [27]. Misdiagnosis has detrimental
outcomes for the patient; with inappropriate treatment leading to an increased severity
of infection and, in extreme cases, surgical intervention, keratoplasty, is required [25]. A
2-year case report study found that 69% (73/106) of individuals with AK were not initially
diagnosed [28]. A patient’s history (e.g., management of their contact lens or corneal injury)
can provide important clues to help distinguish between differential diagnoses, and to
choose the most suitable laboratory methods for the detection and identification of the
causative agent [25]. In the context of veterinary medicine, it would be important to take
note of the animal’s recent travel destinations, immune- and feral-status.
Diagnostic tools include direct microscopic examination of corneal scrapings [15],
molecular tests and culturing [18,19]. Optimal specimens for laboratory diagnostic tests in-
clude corneal scrapings [15] or conjunctival swabs [18] of the infected eye. Wet microscopic
mounts on a warmed slide are useful for examining the specimen [20,23,25]. However, a
subsequent confirmatory laboratory diagnosis is required as microscopic diagnosis can be
subjective [29] with the possibility of human error in confirming that the observed rounded
structures are indeed Acanthamoeba trophozoites and cysts. Isolation of Acanthamoeba can
be achieved using a non-nutrient agar plate seeded with Escherichia coli [15,18,25] or, in
axenic cultures, in protease peptone-yeast extract-glucose media [12]. However, these
conventional techniques may lack sensitivity and the true Acanthamoeba prevalence may
be underestimated [29]. Culturing may also take several days before results can be anal-
ysed [29] and an ideal diagnostic tool needs to provide results relatively quickly to address
appropriate treatment options.
Molecular biology methods, such as PCR, that amplify the nucleic acids of Acan-
thamoeba have been developed to enhance the management of amoebic infections. Although
PCR can detect the presence of Acanthamoeba, a positive PCR result is not necessarily in-
dicative of an active infection as genetic information from viable and nonviable organisms
can both show up as positive. The fact that Acanthamoeba can be present in the eyes of
cats with [16,17] or without [15] AK, and in the corneas of wild birds with or without
keratitis [19], further substantiates this assumption. Future research should explore the
correlation between the presence of Acanthamoeba organisms in the eye of a given animal
and the risk of developing AK. PCR kits are often used only by referral and research
laboratories to identify the amoeba at species level [25], rather than commercially. A
previous study, which compared all the published molecular methods, found that real
time quantitative PCR (qPCR) had the highest sensitivity at 89.3% and the lowest limit of
detection of 0.1 organism/microliter [30]. While qPCR is more expensive than traditional
methods, the benefits of high sensitivity outweigh the costs of unnecessary treatments and
the complications involved with misdiagnosed AK. Molecular diagnostic tools in animals
include screening methods such as PCR and 18S rRNA sequencing [15,18,19]. In another
study, involving a rabbit model of human AK infection, confirmation of the infection was
established by microscopically examining corneal tissue samples, culturing and measuring
the serum IgG titre using an enzyme-linked immunosorbent assay [10].
5. Treatment Options
The standard treatment for AK in humans involves the administration of biguanide
antiseptic eyedrops, for example 0.02% chlorhexidine (CHX) and polyhexamethylene
biguanide (PHMB). The diamidines (e.g., propamidine and hexamidine) are also often used
to treat AK [1]. The usefulness of CHX and PHMB has been investigated [31]. However,
treatment was highly demanding with human patients being expected to administer eye-
drops hourly for the first two days. This meant waking up every hour throughout the
night to administer eye-drops. The dosage was then reduced to hourly within the day for
the next 5 days with a further reduction to four times per day over the succeeding weeks.
CHX and PHMB are not normally administered alone and other drugs are also used, such
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as topical steroids (dexamethasone, 0.1%) for treating corneal inflammation, cycloplegics
(atropine) for photophobia and oral nonsteroidal anti-inflammatories for patients suffering
with sclerokeratitis. This rigorous treatment routine is often necessary as AK is usually
diagnosed when the disease has become more severe. The use of topical steroids in AK
treatment remains contentious. Topical dexamethasone has been shown to increase the
pathogenicity of Acanthamoeba infection in Chinese hamsters [32] and to exacerbate AK
in the rabbit cornea [33]. In contrast, using topical corticosteroids after the initiation of
anti-acanthamoebic therapy, does not seem to worsen the clinical outcomes of AK [34].
Acanthamoeba presents a challenge when the active (trophozoite) form is exposed
to stressful conditions and becomes encysted (Figure 2). In a nationwide 7-year survey
in the Netherlands, 39% of patients’ treatment failed [26]. Common factors associated
with treatment failure include age, delayed diagnosis, and corticosteroid use prior to
diagnosis [26]. There is currently no exclusive drug that can eradicate Acanthamoeba cysts
and trophozoites in humans or animals. Successful treatment relies on a combination of
the anti-amoebic agents biguanide and diamidine [35].
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Based on current veterinary knowledge there are no successful treatments for systemic
or central nervous system amoebiasis in animals [36]. Some examples of effective treatment
against systemic Acanthamoeba infections in humans include antibiotics (e.g., trimethoprim-
sulfamethoxazole, rifampin) and anti-fungals (e.g., ketoconazole) [13,37]. More research
into such drugs should be conducted in order to treat animals suffering from multi-systemic
Acanthamoeba infections. In a dog with a multi-systemic infection, the attempted treatments
included corticosteroid and anti-metabolite therapy [36]. The dog’s condition continued
to deteriorate, suggesting that the pharmacological treatment employed was ineffective.
Unfortunately, this dog died of respiratory arrest associated with infiltration of the lung
interstitial tissue by Acanthamoeba.
Cows and bulls are also susceptible to Acanthamoeba [5]. Research on a triple therapy
of CHX, Na2EDTA and poloxamer (a polymer used to enhance drug delivery) ocular gel,
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using bovine eyes as test material, showed successful anti-amoebic activity when compared
with single drugs [38]. Although this experimental research was on the feasibility of this
approach to the treatment of AK in humans, there is evidence that this drug regimen was
effective as an anti-amoebic agent in bovine eyes. Therefore, it is reasonable to assume
that the same treatment plan can be effective in live cattle and, potentially, other animals
affected with AK. In a similar pharmacological study for the treatment of AK, rats infected
with Acanthamoeba were treated with nine different drug compounds/combinations for
28 days. Cultures were then taken to investigate the existence and extent of Acanthamoeba
development. One drug combination—miltefosine + PHMB—was the most effective
combination, with approximately 86% of rat eye cultures showing no evidence of amoeba
growth after treatment [35]. A topical treatment using miltefosine for AK in Syrian hamsters
has been investigated but was proved to be ineffective [39].
Chronic amoebic keratitis has also been modeled in rats undergoing treatment and
investigated both in vivo and in vitro. In the in vivo model, the amalgamation of PHMB
and hexamidine diisethionate was more potent at destroying Acanthamoeba when com-
pared with the single drugs: PHMB, hexamidine diisethionate and miltefosine [40]. This
study again reinforces that drug combination therapies have shown the most success
against AK. Rabbits have also been used as AK models to determine the risk factor of
using corticosteroids as a treatment option [33]. The rabbits’ eyes were co-inoculated
with Acanthamoeba and the bacterium P. aeruginosa, in either high or low concentrations.
Treatment involved eye-drops containing the steroid Betamethasone sodium phosphate.
The topical corticosteroids were found to worsen AK in two scenarios: firstly, when the
cornea was already infected with Acanthamoeba and high numbers of the bacteria; secondly,
when the administration of the corticosteroid was delayed and the Acanthamoeba infection
was allowed to become established—even in the presence of a small number of bacteria. In
this case, the steroids only aggravated the AK and provided no therapeutic benefit.
6. Unconventional Treatment Options
Dry Eye Syndrome has traditionally been treated with artificial tear products. Magnet
and colleagues investigated whether artificial tears had amoebicidal properties [41]. Two
products, Artelac® Splash (Bausch and Lomb, Berlin, Germany) and Optava FusionTM
(containing Purite®, Allergan, Westport, Ireland), showed limited amoebicidal activity.
However, Oculotect® (Laboratoires Alcon, Kaysersberg, France) showed promising results
and there all Acanthamoeba T4 trophozoites had died within 2 h [41]. It is important
to note that these artificial tear compounds were tested only on Acanthamoeba cultures
and conclusions about the success rate in humans and animals remain to be confirmed.
Amniotic membrane transplantation is another promising approach that has been explored
in human ophthalmology as a means of accelerating wound healing and controlling
inflammation [42].
7. Conclusions
There is evidence for the existence of AK in animals; however, AK appears to be
an underdiagnosed condition and none of the studies reviewed herein have suggested
how veterinarians should diagnose and treat infected animals. Therefore, it is too early to
infer how prevalent AK is in the UK and other countries. Given the ubiquitous presence
of Acanthamoeba throughout the world, it is important to consider AK as a differential
diagnosis when presented with keratitis particularly if the animal has travelled to or from
areas where Acanthamoeba has been reported. It is important to bear in mind that, although
acanthamoebiasis is a rare infectious disease, it should be considered in the differential
diagnosis of systemic diseases and neurologic involvement as infected animals can be also
present with fever, anorexia, limb stiffness, signs of neurological impairment and peritonitis,
among other symptoms. More studies are needed to explore the prevalence of amoebae
in domestic animals. Given the limited evidence of diagnostic, and treatment, options for
animals infected with Acanthamoeba future studies should investigate AK pathophysiology
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in animals. This would permit for the development of a classification system, ultimately
improving AK diagnosis.
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